UroGen Pharma (URGN) Posts Smaller Q1 Loss

UroGen Pharma (NASDAQ: URGN) reported Q1 EPS of ($1.07), $0.26 better than the analyst estimate of ($1.33).

As of March 31, 2022, cash and cash equivalents were $138.1 million plus an additional $150 million in liquidity for which Phathom is eligible to receive, which includes $100 million in proceeds from the revenue interest financing agreement announced on May 4, 2022 and $50 million from its term loan with Hercules Capital.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M